Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $160.00 USD
Change Today -3.42 / -2.09%
Volume 2.1M
ALXN On Other Exchanges
As of 5:20 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

352 Knotter Drive

Cheshire, CT 06410

United States

Phone: 203-272-2596

Fax: 203-271-8198

The company has completed two natural history studies in infantile-onset patients with HPP and juveniles with HPP. cPMP (ALXN 1101) Molybdenum Cofactor Deficiency (MoCD) Disease Type A (MoCD Type A): MoCD Type A is an ultra-rare metabolic disorder characterized by severe and rapidly progressive neurologic damage and death in newborns. ALXN 1007: ALXN 1007 is a novel humanized antibody designed to target rare and severe inflammatory disorders and is a product of the company’s proprietary antibody discovery technologies. The company has completed enrollment in both a Phase I single-dose, dose escalating safety and pharmacology study in healthy volunteers, as well as in a multi-dose, dose escalating safety, and pharmacology study in healthy volunteers. As a result of meetings with the FDA, the company commenced dosing in 2014 a Phase II proof-of-concept study in patients with anti-phospholipid syndrome (APS). APS is an ultra-rare autoimmune, hypercoagulable state caused by antiphospholipid antibodies. A second proof-of-concept study in patients with another ultra-rare disorder, gastrointestinal graft versus host disease (GI-GVHD) was initiated in September 2014. Patients with GI-GVHD following bone marrow or hematopoietic stem cell transplant experience engrafted hematopoietic cells that attack host gastrointestinal tissues in the first 100 days post-transplant causing damage to the GI tract, liver and skin. Sales and Marketing The company has established a commercial organization to support current and future sales of Soliris in the United States, Europe, Japan, the Asia Pacific countries, and other territories. Customers The company’s customers primarily include distributors, pharmacies, hospitals, hospital buying groups, and other health care providers. In some cases, it might also sell Soliris to governments and government agencies. License and Collaboration Agreements In January 2015, the company entered into a license agreement with a third party to obtain certain intellectual property rights and technology related to specific therapeutic compounds. The agreement provides an exclusive research, development, and commercial license for products to be developed using such compounds. In December 2014, the company entered into an agreement with X-Chem Pharmaceuticals (X-Chem) that allows the company to identify novel drug candidates from X-Chem's proprietary drug discovery engine. The company would have the exclusive worldwide rights to develop and commercialize up to three targets arising from the collaboration. In January 2014, the company entered into an agreement with Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. In July 2013, the company entered into a license and collaboration agreement with Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. In January 2013, the company entered into a license agreement for a technology, which provides an exclusive research license and an option for an exclusive commercial license for specific targets and products to be developed. The company has a license agreement with the Medical Research Council (MRC) whereby MRC granted to the company worldwide non-exclusive rights to certain patents related to the humanization and production of monoclonal antibodies. Intellectual Property Rights With respect to Soliris, the company owns an issued U.S. patent that covers the product and would expire in 2021, taking into account patent term extension. It also owns a corresponding issued European patent that covers Soliris and would expire in 2015, though in certain European countries where the company filed for supplementary protection certificates that it expects exclusivity to extend into 2020. In Japan and other countries where the company owns patents covering Soliris the patents would expire between 2015 and 2020. The company also owns the U.S. and foreign patents and patent applications that pr


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $160.00 USD -3.42

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,777 GBp +11.00
Dr Reddy's Laboratories Ltd 4,247 INR +66.25
Sigma-Aldrich Corp $139.47 USD -0.03
Symrise AG €55.45 EUR -0.109
United Therapeutics Corp $125.28 USD -1.42
View Industry Companies

Industry Analysis


Industry Average

Valuation ALXN Industry Range
Price/Earnings 55.8x
Price/Sales 13.8x
Price/Book 4.3x
Price/Cash Flow 62.4x
TEV/Sales 13.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at